OncoMatch/Clinical Trials/NCT07402915

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Is NCT07402915 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including AZD5335 and Itraconazole for fallopian tube cancer.

Phase 1RecruitingAstraZenecaNCT07402915Data as of May 2026

Treatment: AZD5335 · Itraconazole — The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy

have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum

Must have received: VEGF inhibitor (bevacizumab)

must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible

Must have received: PARP inhibitor

must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify